CJC-1295 (no DAC)

CJC-1295 (no DAC) is a synthetic analog of growth-hormone-releasing hormone (GHRH). Unlike the DAC-modified version, it lacks the Drug Affinity Complex that binds serum albumin to extend half-life — its research duration profile sits closer to native GHRH and to Sermorelin than to long-acting GHRH analogs.

Watch

▶ Real Dr Explains CJC-1295 + Ipamorelin - The CLASSIC Peptide Stack

Mechanism

• GHRH receptor agonism. Binds pituitary GHRH receptors, stimulating a pulsatile release of endogenous growth hormone rather than introducing exogenous GH directly.
• Short half-life. Without DAC, plasma clearance is measured in minutes rather than days, so research protocols typically pair it with more frequent dosing than DAC-modified analogs.

Common research protocols

Dosing information below reflects published research literature. It is not medical advice and is not a treatment plan.

• Route. Subcutaneous injection.
• Research context. Frequently studied alongside GHRP-class secretagogues (e.g. Ipamorelin) to examine synergistic GH-pulse amplitude in research settings.

Evidence at a glance

• Regulatory status. Not FDA-approved. Investigational, studied primarily as a growth-hormone secretagogue in peptide research.
• What we do not know. Comparative pulse-amplitude data against DAC-modified CJC-1295; long-term effects of repeated dosing.

Reconstitution & handling

Lyophilized peptides ship as freeze-dried powder. Reconstitute with bacteriostatic water; refrigerate the reconstituted vial. Use the reconstitution calculator to get syringe-unit readings for your target dose. General reconstitution and syringe guidance in the How We Work page.

Primary-literature list for this guide available on request via contact.